LATITUDE: A landmark trial for high-risk metastatic castration-sensitive prostate cancer: Final overall survival analysis

摘要

LATITUDE was a multicenter, randomized, double-blind, phase 3 trial on high-risk metastatic castration-sensitive prostate cancer (mCSPC).[1] The inclusion criteria were men who fulfilledat least two of the three high-risk prognostic factors (GS ≥8, ≥3 lesions on bone scan, and visceral metastases, excluding lymph node metastasis). It included men withhistologically/cytologically confirmed adenocarcinoma prostate, with distant metastatic disease (documented by positive bone scan or metastatic lesions on computed tomography ormagnetic resonance imaging) and ECOG performance status of 0–2. The exclusion criteria were men with neuroendocrine differentiation/small cell histology, brain metastasis, uncontrolledhypertension, or clinically significant cardiac, adrenal, or liver disease, or malignancy other than prostate or nonmelanoma skin cancer 5 years. Patients who had received previouschemotherapy, radiotherapy, or surgery for metastatic prostate were also excluded from the study.